Teva Gets Court Decision Regarding Generic Prevacid SoluTab

Posted on: Thu, 12 Nov 2009 00:19:00 EST


Symbols: TEVA
Nov 12, 2009 (Close-Up Media via COMTEX) --
TEVA | Quote | Chart | News | PowerRating -- Teva Pharmaceutical Industries announced that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid (Lansoprazole) SoluTab.

In a release, the Company noted that the Court found that its generic lansoprazole orally disintegrating tablets do not infringe U.S. Patent No. 5,464,632. Teva intends to complete an analysis of the decision before deciding upon its next course of action.

Annual sales of the brand product were approximately $500 million in the United States for the twelve months that ended June 30, based on IMS sales data.

((Comments on this story may be sent to health@closeupmedia.com))

For full details on Teva Pharm Ind (TEVA) TEVA. Teva Pharm Ind (TEVA) has Short Term PowerRatings at TradingMarkets. Details on Teva Pharm Ind (TEVA) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.